109202 ⎘
Structure or type of the nucleic acid; Chemical structure; Nature of the modification linked to the nucleic acid via a carbon atom MOE, methoxyethoxy
Modulation of Stat 6 Expression for the Treatment of Airway Hyperresponsiveness
#302ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EXPRESSION
#303Antisense compounds
#3045'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom
#305OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA
#306Methods for treating hypercholesterolemia
#307MODULATION OF eIF4E EXPRESSION
#308Methods for treating multiple sclerosis using antisense oligonucleotides
#309Modulation of HIF1-beta expression
#310METHODS FOR SLOWING FAMILIAL ALS DISEASE PROGRESSION
#311COMPOSITIONS AND THEIR USES DIRECTED TO HUNTINGTIN
#312Combination therapy using budesonide and antisense oligonucleotide targeted to IL4-receptor alpha
#313EFFICIENT REDUCTION OF TARGET RNA'S BY SINGLE- AND DOUBLE-STRANDED OLIGOMERIC COMPOUNDS
#314Antisense modulation of connective tissue growth factor expression
#315Short interfering ribonucleic acid (siRNA) with improved pharmacological properties
#316ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
#317Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#318Compositions and their uses directed to IL-4R alpha
#319CONJUGATED DOUBLE STRAND COMPOSITIONS FOR USE IN GENE MODULATION
#320Regulation of epigenetic control of gene expression
#321Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#322MODULATION OF STAT 6 EXPRESSION
#323Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#324Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#325Silencing of polo-like kinase expression using interfering RNA
#326Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs
#327Modulation of insulin like growth factor I receptor expression
#328Compositions and Their Uses Directed to IL-4R Alpha
#329STABILIZED SIRNAS AS TRANSFECTION CONTROLS AND SILENCING REAGENTS
#330Antisense modulation of C-reactive protein expression
#331MODULATION OF TUDOR-SN EXPRESSION
#332HUMAN RNASE III AND COMPOSITIONS AND USES THEREOF
#333Oligomeric compounds and compositions for the use in modulation of microRNAs
#334MODULATION OF LMW-PTPASE EXPRESSION
#335MODULATION OF CHREBP EXPRESSION
#336ANTISENSE COMPOUNDS HAVING ENHANCED ANTI-MICRORNA ACTIVITY
#337Modulation of eIF4E-BP2 expression
#338Modified short interfering RNA
#339Interfering RNA duplex having blunt-ends and 3′-modifications
#340Modulation of eIF4E expression
#341MODULATION OF STAT 6 EXPRESSION FOR THE TREATMENT OF AIRWAY HYPERRESPONSIVENESS
#342Interfering RNA molecules
#343Modulation of C-reactive protein expression
#344MODULATION OF ENDOTHELIAL LIPASE EXPRESSION
#345MicroRNAs
#346Antisense modulation of PTP1B expression
#347MODULATION OF INSULIN LIKE GROWTH FACTOR I RECEPTOR EXPRESSION
#348Modulating Gene Expression with agRNA and Gapmers Targeting Antisense Transcripts
#349Modulation of eIF4E-BP2 expression
#350Modulation of transthyretin expression
#351Modulation of apolipoprotein (a) expression
#352Topical administrations of antisense compounds to VLA-4 for the treatment of respiratory conditions
#353Antisense oligonucleotides for prevention of metastasis formation of cancer cells
#354Isis Pharmaceuticals, Inc.
#355Compositions and their uses directed to PTPRU
#356RNAi probes targeting cancer-related proteins
#357Compositions and methods for the modulation of JNK proteins
#358Antisense modulation of apolipoprotein B expression
#359Compositions and methods for optimizing cleavage of RNA by RNase H
#360Method For Preventing or Treating Pain in a Mammal
#361Methods for the Delivery of Oligomeric Compounds
#362Antisense modulation of p38 mitogen activated protein kinase expression
#363ANTISENSE MODULATION OF ACYL COA CHOLESTEROL ACYLTRANSFERASE-2 EXPRESSION
#364Modulation of FR-alpha expression
#365Treatment of neurological disorders by dsRNA administration
#366Modulation of forkhead box O1A expression
#367Antisense modulation of stearoyl-CoA desaturase expression
#368Positionally modified siRNA constructs
#369Clusterin antisense therapy for treatment of cancer
#370COMPOSITIONS AND THEIR USES DIRECTED TO IL-4R ALPHA
#371TRPM-2 antisense therapy
#372ANTISENSE OLIGONUCLEOTIDE MODULATION OF STAT3 EXPRESSION
#373Compositions and their uses directed to huntingtin
#374Antisense modulation of kinesin-like 1 expression
#375BACKBONE MODIFICATIONS TO MODULATE OLIGONUCLEOTIDE TARGETING IN VIVO
#376COMPOSITIONS AND THEIR USES DIRECTED TO HUNTINGTIN
#377Modulation of STAT5 expression
#378Human RNase H1 oligonucleotide compositions thereof
#379Compositions and their uses directed to hepcidin
#380THERAPEUTIC DRUG COMBINATIONS AND DELIVERY SYSTEMS COMPRISING C-RAF KINASE ANTISENSE POLYNUCLEOTIDES FOR TREATING OCULAR DISEASES AND DISORDERS
#381Oligonucleotide and the use thereof for modulating an isoform C beta-1 protein-kinase in the form of a skin depigmentation agent
#382Stabilized siRNAs as transfection controls and silencing reagents
#383MODULATION OF THYROID HORMONE RECEPTOR INTERACTOR 3 EXPRESSION
#384Compositions and methods for non-parenteral delivery of oligonucleotides
#385Modulation of glucagon receptor expression
#386MODULATION OF GLUCAGON RECEPTOR EXPRESSION
#387MODULATION OF GLUCAGON RECEPTOR EXPRESSION
#388MODULATION OF GLUCAGON RECEPTOR EXPRESSION
#389MODULATION OF ACE2 EXPRESSION
#390Interfering Rna Duplex Having Blunt-Ends And 3'-Modifications
#391Modulation of ace2 expression
#392Antisense IAP nucleobase oligomers and uses thereof
#393COMPOSITIONS AND THEIR USES DIRECTED TO IL-4R ALPHA
#394Compositions and their uses directed to IL-4R alpha
#395Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
#396Antisense IAP nucleobase oligomers and uses thereof
#397Compositions and methods for the modulation of the expression of B7 protein
#398Methods for slowing familial ALS disease progression
#399Modulation of glucagon receptor expression
#400Modulation of glucocorticoid receptor expression
#401Modulation of eIF4E expression
#402Antisense modulation of superoxide dismutase 1, soluble expression
#403Methods for use in modulating miR-122a
#404Antisense modulation of fibroblast growth factor receptor 3 expression
#405Antisense IAP nucleobase oligomers and uses thereof
#406Antisense IAP nucleobase oligomers and uses thereof
#407Modulation of SOCS-3 expression
#408Modulation of HIF1alpha and HIF2alpha expression
#409Modulation of endothelial lipase expression
#410Antisense permeation enhancers
#411Antisense modulation of superoxide dismutase 1, soluble expression
#412Modulation of apolipoprotein (A) expression
#413Modulation of STAT 6 expression for the treatment of airway hyperresponsiveness
#414Oligomeric compounds and compositions for use in modulation of pri-mirnas
#415Modulation of HIF-1 beta expression
#416Compositions and their uses directed to thymus and activation-regulated chemokine (TARC)
#417Modulation of insulin like growth factor I receptor expression
#418Antisense oligonucleotide modulation of STAT3 expression
#419Antisense modulation of farnesoid X receptor expression
#420RNAi probes targeting cancer-related proteins
#421Antisense modulation of integrin beta 4 binding protein expression
#422Modulation of glucocorticoid receptor expression
#423Antisense modulation of CD40 ligand expression
#424Cell permeable nanoconjugates of shell-crosslinked knedel (SCK) and peptide nucleic acids (“PNAs”) with uniquely expressed or over-expressed mRNA targeting sequences for early diagnosis and therapy of cancer
#425Modulation of SLC26A2 expression
#426Antisense oligonucleotide modulation of raf gene expression
#427Down-regulation of target-gene with pei/single-stranded oligoribonucleotide complexes
#428Use of mob-5 in pain
#429Antisense modulation of vegf co-regulated chemokine-1 expression
#430Antisense modulation of hydroxysteroid 11-beta dehydrogenase 1 expression
#431Nuclease resistant double-stranded ribonucleic acid
#432Antisense oligonucleotides for identifying drug targets and enhancing cancer therapies
#433Conjugates for use in hepatocyte free uptake assays
#434Antisense modulation of matrix metalloproteinase 1 expression
#435Oligomeric compounds effecting drosha-mediated cleavage
#436Enhanced antisense oligonucleotides
#437Antisense modulation of hematopoietic cell protein tyrosine kinase expression
#438Antisense oligonucleotides directed to genes regulated by trapoxin-induced HDAC inhibition
#439Methods for modulating lipoprotein and cholesterol levels in humans
#440Treatment of neurological disorders by dsrna administration
#441Antisense modulation of c/ebp beta expression
#442Modulation of glucocorticoid receptor expression
#443Antisense modulation of PTP1B expression
#444Antisense modulation of C-reactive protein expression
#445Effects of apolipoprotein B inhibition on gene expression profiles in animals
#446Bispecific oligonucleotide for the treatment of CNS malignancies
#447Modulation of growth hormone receptor expression and insulin-like growth factor expression
#448Antisense modulation of ptpn12 expression
#449Modulation of Aurora B expression
#450Antisense modulation of p70 S6 kinase expression
#451Modulation of glucose-6-phosphatase translocase expression
#452Antisense modulation of interleukin 12 P35 subunit expression
#453Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#454Modulation of pumilio 1 expression
#455Modulation of Nanos 1 expression
#456Antisense modulation of cellular apoptosis susceptibity gene expression
#457Double stranded constructs comprising one or more short strands hybridized to a longer strand
#458Modulation of transthyretin expression
#459Modulation of STAT 6 expression
#460Modulation of kallikrein 6 expression
#461Antisense modulation of TFAP2C expression
#462Antisense modulation of thyroid hormone receptor interactor 6 expression
#463Antisense modulation of mucin 1, transmembrane expression
#464Hepatocyte free uptake assays
#465Modulation of tyrosinase expression
#466Antisense modulation of sterol regulatory element-binding protein-1 expression
#467Compositions and their uses directed to signal transducers
#468Antisense modulation of cellular inhibitor of Apoptosis-2 expression
#469Antisense modulation of dual specific phosphatase 5 expression
#470Modulation of eIF4E-BP2 expression
#471Modulation of SGLT2 expression
#472Compositions and their uses directed to cell growth and maintenance proteins
#473Antisense modulation of peroxisome proliferator-activated receptor gamma expression
#474Antisense modulation of EIF2C1 expression
#475Modulation of DC-SIGN expression
#476Modulation of eIF4E-BP1 expression
#477Antisense modulation of microsomal triglyceride transfer protein expression
#478Compositions and their uses directed to binding proteins
#479Modulation of glucocorticoid receptor expression
#480Compositions and their uses directed to metabolic proteins
#481Methods of using mammalian RNase H and compositions thereof
#482Hepatocyte free uptake assays
#483Human RNase III and compositions and uses thereof
#484Compositions and their uses directed to transferases
#485Antisense modulation of interferon gamma receptor 2
#486Methods of using mammalian RNase H and compositions thereof
#487Antisense modulation of extracellular-signal-regulated kinase-6 expression
#488Human RNase H and compositions and uses thereof
#489Compositions and their uses directed to nucleic acid binding proteins
#490Antisense oligonucleotides against tenascin for the treating of vitiligo
#491Antisense modulation of survivin expression
#492Antisense modulation of phospholipase A2, group IIA (synovial) expression
#493Microrna as ligands and target molecules
#494Antisense modulation of cholesteryl ester transfer protein expression
#495Compositions and their uses directed to signal tranducers
#496Conjugated oligomeric compounds and their use in gene modulation
#497Antisense oligonucleotides optimized for kidney targeting
#498Antisense modulation of inducible nitric oxide synthase expression
#499Antisense modulation of polo-like kinase expression
#500Modulation of CEACAM1 expression
#501Antisense modulation of PLML expression
#502Antisense modulation of caspase 7 expression
#503Antisense modulation of calreticulin expression
#504Modulation of STAT5 expression
#505Modulation of phosphodiesterase 4B expression
#506Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)
#507Notch1 inhibitors for inducing apoptosis
#508Antisense modulation of PTP1B expression
#509Modulation of aminopeptidase N expression
#510Antisense modulation of wrn espression
#511Antisense oligonucleotide modulation of STAT3 expression
#512Antisense modulation of ptpn2 expression
#513Antisense modulation of acyl coenzyme a cholesterol acyltransferase-1 expression
#514Mouse model for bone metabolism
#515Antisense modulation of connective tissue growth factor expression
#516Structural motifs and oligomeric compounds and their use in gene modulation
#517Antisense oligonucleotide modulation of tumor necrosis factor-alpha (TNF-alpha) expression
#518Antisense modulation of insulin-like growth factor binding protein 5 expression
#519Antisense modulation of stearoyl-CoA desaturase expression
#520Phosphorous-linked oligomeric compounds and their use in gene modulation
#521Modulation of the RNA interference pathway
#522Antisense modulation of breast cancer-1 expression
#523Antisense modulation of superoxide dismutase 1, soluble expression
#524Modulation of glucagon receptor expression
#525Modulation of C-reactive protein expression
#526Antisense modulation of hypothetical protein LOC51249 expression
#527Antisense modulation of apolipoprotein B-expression
#528Conjugated antisense compounds and their use
#529Compounds and methods for reducing LRRK2 expression